Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QHK9 | ISIN: US82835W1080 | Ticker-Symbol:
NASDAQ
06.06.25 | 16:46
13,820 US-Dollar
+2,98 % +0,400
1-Jahres-Chart
ARS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ARS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ARS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.05.ARS Pharmaceuticals GAAP EPS of -$0.35 in-line, revenue of $7.97M beats by $0.49M13
14.05.ARS Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
14.05.ARS Pharmaceuticals, Inc. - 8-K, Current Report1
08.05.ARS Pharma's epinephrine nasal spray 1mg now available in US1
02.05.ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy4
02.05.ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians1
02.05.ARS Pharmaceuticals, Inc. - 8-K, Current Report1
ARS PHARMACEUTICALS Aktie jetzt für 0€ handeln
24.03.Raymond James lifts ARS Pharmaceuticals price target to $323
22.03.ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript5
20.03.ARS Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
20.03.ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion6
20.03.ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.1
20.03.Raymond James maintains $28 target on ARS Pharma stock2
20.03.ARS Pharmaceuticals GAAP EPS of $0.08, revenue of $89.15M2
20.03.ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates511$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing...
► Artikel lesen
20.03.ARS Pharmaceuticals, Inc. - 10-K, Annual Report-
20.03.ARS Pharmaceuticals, Inc. - 8-K, Current Report1
07.03.US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients (March 5)2
06.03.FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment1
06.03.ARS Pharma: FDA Approves Neffy 1 Mg For Type I Allergic Reactions In Pediatric Patients2
Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1